Icon

ICLR

Market cap $14.6B

Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DUBLIN--(BUSINESS WIRE)--ICON plc Schedules Third Quarter 2025 Earnings Conference Call.

DUBLIN--(BUSINESS WIRE)--ICON Announces CEO Transition.

DUBLIN--(BUSINESS WIRE)--ICON plc to Participate at Upcoming Investor Conferences.

In the world of healthcare stocks, a major innovation, new medical device, or successful drug treatment can cement a firm's position as a leader. Unfortunately, many firms chase after these goals and never achieve them.

ICON Public Limited Company (NASDAQ:ICLR ) Q2 2025 Earnings Conference Call July 24, 2025 8:00 AM ET Company Participants Barry Balfe - Chief Operating Officer Kate Haven - Vice President of Investor Relations Nigel Clerkin - Chief Financial Officer Steven A. Cutler - CEO & Director Conference Call Participants Charles Rhyee - TD Cowen, Research Division David Howard Windley - Jefferies LLC, Research Division Elizabeth Hammell Anderson - Evercore ISI Institutional Equities, Research Division Eric White Coldwell - Robert W.

ICON may be relatively undervalued, trading at a ~10% discount to IQVIA and offering an attractive ~7% free cash flow yield that markets seem to be responding to now. The CRO sector faces near-term headwinds from a weak biotech funding environment related to high interest rates and associated increased clinical trial cancellations and delays. Q2 is indicating to markets that there will eventually be a return to growth after the CRO industry comes off the easy-money-fueled innovation environment.

Icon PLC (ICLR) came out with quarterly earnings of $3.26 per share, beating the Zacks Consensus Estimate of $3.18 per share. This compares to earnings of $3.75 per share a year ago.

DUBLIN--(BUSINESS WIRE)--ICON Announces Results of Annual General Meeting.

DUBLIN--(BUSINESS WIRE)--ICON Reports Second Quarter 2025 Results.